Entero Healthcare Q1FY27: Revenue Jumps 38.2% to ₹1,940 Cr, EBITDA Up 94%
Entero Healthcare Solutions reported Q1FY27 results with consolidated revenue up 38.2% YoY to ₹1,940 crore. EBITDA surged 94% to ₹97 crore, and EBITDA margins improved to 5.0%. ROCE improved to 21.0% and ROE to 20.4%. The company aims for ₹1,000 crore in MedTech revenue by FY27.
The substantial revenue growth, improved profitability metrics, and positive outlook presented in the investor presentation are material to investors and indicate a significant positive development for the company.
The company reported strong year-on-year growth in revenue, EBITDA, and margins, along with significant improvements in return ratios. This indicates a positive financial performance.
Entero Healthcare Solutions Limited announced its unaudited financial results for the quarter ended June 30, 2026 (Q1FY27), presenting an investor presentation on the same.
The company reported a consolidated revenue growth of 38.2% year-on-year (YoY) to ₹1,940 crore. On a like-for-like (LFL) basis, consolidated revenue grew by 40.0% YoY. EBITDA margins improved significantly by 143 basis points YoY to 5.0%, with EBITDA increasing by 94% YoY to ₹97 crore. Gross margin also saw an improvement of 147 bps YoY to 11.4%.
Profit After Tax (PAT) to owners grew by 37% YoY to ₹38.2 crore. Return on Capital Employed (ROCE) nearly doubled YoY to 21.0%, and Return on Equity (ROE) stood at 20.4%, up from 9.0% in Q1FY26. Net Operating Working Capital days improved to 61 days from 66 days in the previous year.
The company highlighted strong organic revenue growth of 19.6% YoY on an LFL basis, while reported organic growth was 17.8% YoY. Inorganic growth was 20.4%, attributed to calendarization. Entero aims to cross ₹1,000 crore in MedTech revenue by FY27.
The investor presentation also detailed the company's operational highlights, including an increase in hospital customers to 2,300+ and retail customers to over 72,000. The company continues to expand its distribution network, covering 475 districts across 19 states with 138 warehouses.
Entero emphasized its differentiated business model, proprietary technology platform, and experienced management team as key strengths. The company is well-positioned to benefit from the ongoing consolidation in the highly fragmented Indian healthcare products distribution market, with the share of large national distributors expected to rise significantly.
What to do with a filing like this
Entero Healthcare Solutions Limited filed this with the NSE as a statutory disclosure, categorised under quarterly results. It is a primary document, not a recommendation, and the desk marks it high impact, which is the band that most often changes something.
That call is the part a filing cannot make for you. On RealCase, SEBI-registered research analysts and investment advisers read announcements like this one and turn the ones that matter into actions inside their model portfolios: a change in weight, a hold, or nothing at all. You are not left working out which of the roughly 250 filings published each day needs a response. The portfolio you follow is updated when a filing actually warrants it, with the reason written down.
See the model portfoliosA plain-language summary of a public exchange filing by Entero Healthcare Solutions Limited. Read the original for the full detail.